Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990846 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
A Phase 1 study of Influenza, sponsored by Autoimmune Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT01990846: Completed Phase 1 study of Influenza, sponsored by Autoimmune Technologies.
NCT01990846 is a Phase 1 study of Influenza that has completed, run by Autoimmune Technologies. The registered enrollment target is 68 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01990846, a Phase 1 study of Influenza, has completed, sponsored by Autoimmune Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
Conditions Studied
Interventions
- DRUG Flufirvitide 3
- DRUG Placebo for Flufirvitide-3
Study Locations (1)
South Carolina
- Spartanburg Medical Research - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
What the finished NCT01990846 record still lists
NCT01990846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Flufirvitide 3 is the first listed.
NCT01990846 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT01990846 about?
NCT01990846 is a clinical study titled "Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects". To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
What is the current status of trial NCT01990846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2014-03. Estimated completion is 2015-02.
What conditions does trial NCT01990846 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01990846?
The interventions under investigation include: Flufirvitide 3 (DRUG), Placebo for Flufirvitide-3 (DRUG).
Who is sponsoring clinical trial NCT01990846?
This trial is sponsored by Autoimmune Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01990846 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01990846's enrollment target sits among peer trials
68 116th of 156 higher than 41 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia